{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:08:57Z","timestamp":1780463337165,"version":"3.54.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Provocative coronary vasospasm testing requires intracoronary acetylcholine (ACh) administration, however an ACh drug formulation approved for intracoronary use is not commercially available. Invasive coronary vasomotor testing programs have thus resorted to reconstituting and diluting ophthalmic ACh solutions for off-label and off-target intracoronary use, despite a lack of comprehensive ACh stability testing data required by pharmacy compounding regulations USP &amp;lt;797\u2009&amp;gt;\u2009. This study aims to characterize the stability of compounded ACh intraocular solutions according to current pharmacy guidelines for use in provocative intracoronary ACh vasospasm testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Potency and stability testing was performed by an FDA and DEAS registered, A2LA ISO 17025:2017 accredited laboratory. Using a simple, 7-step compounding method, a single vial of intraocular ACh solution was reconstituted and diluted with 500\u2005mL of dextrose 5% water (D5W) to a final concentration of 18.2 mcg\/mL. Compounded ACh was then stored in 20\u2005mL syringes at ambient room temperature (25\u2009\u00b1\u20092\u2005\u00b0C and 60\u2009\u00b1\u20095% relative humidity) under normal fluorescent lighting to simulate routine cardiac catheterization laboratory conditions. The compounded ACh solution appearance, pH, particulate matter, concentration and potency were evaluated in triplicate at 0, 4, and 12\u2005h after compounding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The compounded ACh solution was clear and colorless with a pH of 4.2 across all time points. Subvisible particulate matter, assessed by light obscuration techniques, demonstrated that the quantity of &amp;gt;10\u2005\n                      <jats:italic>\u03bc<\/jats:italic>\n                      m and &amp;gt;25\u2005\n                      <jats:italic>\u03bc<\/jats:italic>\n                      m particles present in each syringe remained safely within USP &amp;lt;788\u2009&amp;gt;\u2009specifications. Finally, using high-performance liquid chromatography \u2013 mass spectrometry, the compounded ACh solutions revealed no significant degradation during the studied time frame, with 96.7\u2009\u00b1\u20090.3% of the initial ACh retained at 12\u2005h, satisfying USP &amp;lt;797\u2009&amp;gt;\u2009regulations to maintain 90.0% - 110.0% of label claim (18.2 mcg\/mL).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Utilizing a novel compounding method, intraocular ACh reconstituted and diluted in D5W met all USP &amp;lt;797\u2009&amp;gt;\u2009pharmacy stability regulatory criteria over 12\u2005h under ambient room temperature storage conditions. This study thus establishes a simplified ACh compounding approach for invasive coronary function testing centers to generate an intracoronary ACh drug formulation for use within 12\u2005h in provocative coronary vasospasm testing procedures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1802503","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:53:04Z","timestamp":1780462384000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmaceutical stability of compounded acetylcholine chloride intraocular solution for intracoronary provocative vasospasm testing"],"prefix":"10.3389","volume":"13","author":[{"given":"Killian J.","family":"McCarthy","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Greenhalgh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beth Israel Deaconess Medical Center , Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beth Israel Deaconess Medical Center , Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cedro","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beth Israel Deaconess Medical Center , Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duane","family":"Pinto","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Stephan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beth Israel Deaconess Medical Center , Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Osborn","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1161\/CIRCULATIONAHA.116.024534","article-title":"Ischemia and No obstructive coronary artery disease (INOCA): developing evidence-based therapies and research agenda for the next decade","volume":"135","author":"Bairey Merz","year":"2017","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1136\/heartjnl-2019-315042","article-title":"Diagnosis of patients with angina and non-obstructive coronary disease in the catheter laboratory","volume":"105","author":"Rahman","year":"2019","journal-title":"Heart"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1016\/j.jacc.2018.09.042","article-title":"Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC state-of-the-art review","volume":"72","author":"Taqueti","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1056\/NEJMoa0907272","article-title":"Low diagnostic yield of elective coronary angiography","volume":"362","author":"Patel","year":"2010","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1093\/eurheartj\/ehy857","article-title":"Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularization","volume":"40","author":"Crea","year":"2019","journal-title":"Eur Heart J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1161\/01.CIR.0000130642.79868.B2","article-title":"Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: results from the National Institutes of Health\u2013National Heart, Lung, and Blood Institute-sponsored women's Ischemia syndrome evaluation (WISE)","volume":"109","author":"Johnson","year":"2004","journal-title":"Circulation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e003863","DOI":"10.1161\/CIRCOUTCOMES.116.003863","article-title":"Ten-Year mortality in the WISE study (Women's Ischemia syndrome evaluation)","volume":"10","author":"Kenkre","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"B8","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1093\/eurheartj\/ehr331","article-title":"Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events","volume":"33","author":"Jespersen","year":"2012","journal-title":"Eur Heart J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1016\/j.jcin.2020.05.009","article-title":"Long-Term follow-up in patients with stable angina and unobstructed coronary arteries undergoing intracoronary acetylcholine testing","volume":"13","author":"Seitz","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"B10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ijcard.2021.02.079","article-title":"Vasomotor dysfunction in patients with angina and nonobstructive coronary artery disease is dominated by vasospasm","volume":"333","author":"Konst","year":"2021","journal-title":"Int J Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1016\/j.jacc.2018.09.006","article-title":"Stratified medical therapy using invasive coronary function testing in angina: the CorMicA trial","volume":"72","author":"Ford","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e008126","DOI":"10.1161\/CIRCINTERVENTIONS.119.008126","article-title":"Ischemia and No obstructive coronary artery disease: prevalence and correlates of coronary vasomotion disorders","volume":"12","author":"Ford","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"B13","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.105.609990","article-title":"The economic burden of angina in women with suspected ischemic heart disease: results from the national institutes of health\u2013national heart, lung, and blood institute\u2013sponsored Women's Ischemia syndrome evaluation","volume":"114","author":"Shaw","year":"2006","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/archinternmed.2009.50","article-title":"Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the women's Ischemia syndrome evaluation study and the St James women take heart project","volume":"169","author":"Gulati","year":"2009","journal-title":"Arch Intern Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1161\/CIR.0000000000001394","article-title":"State of the art: evaluation and medical management of nonobstructive coronary artery disease in patients with chest pain: a scientific statement from the American Heart Association","volume":"152","author":"Slipczuk","year":"2025","journal-title":"Circulation"},{"key":"B16","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1093\/eurheartj\/ehaf839","article-title":"Endotypes of angina with non-obstructive coronary arteries: a prospective multicentre study","volume":"47","author":"Miner","year":"2025","journal-title":"Eur Heart J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.jacc.2023.06.043","article-title":"Comprehensive management of ANOCA, part 1\u2014definition, patient population, and diagnosis: JACC state-of-the-art review","volume":"82","author":"Samuels","year":"2023","journal-title":". J Am Coll Cardiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jcin.2012.01.023","article-title":"Safety of coronary reactivity testing in women with No obstructive coronary artery disease: results from the NHLBI-sponsored Women's Ischemia syndrome evaluation (WISE) study","volume":"5","author":"Wei","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"B21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/eurheartj\/ehx667","article-title":"Patients with acute myocardial infarction and non-obstructive coronary arteries: safety and prognostic relevance of invasive coronary provocative tests","volume":"39","author":"Montone","year":"2018","journal-title":"Eur Heart J"},{"key":"B22","first-page":"2878","article-title":"Effects of acetylcholine on the coronary artery","volume":"43","author":"Vanhoutte","year":"1984","journal-title":"Fed Proc"},{"key":"B23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/eye.1999.78","article-title":"Muscarinic receptor functioning and distribution in the eye: molecular basis and implications for clinical diagnosis and therapy","volume":"13","author":"Nietgen","year":"1999","journal-title":"Eye (Basingstoke)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"132640","DOI":"10.1016\/j.ijcard.2024.132640","article-title":"Assessment of coronary endothelial dysfunction using contemporary coronary function testing","volume":"418","author":"de Jong","year":"2025","journal-title":"Int J Cardiol"},{"key":"B25","volume-title":"Physiology, Acetylcholine","author":"Sam","year":"2023"},{"key":"B26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.5688\/ajpe7710233","article-title":"Remington: essentials of pharmaceutics. Pharmaceutical press; 2013, 772pp, $69.00 (softcover), ISBN 9780857111050","volume":"77","author":"Almoazen","year":"2013","journal-title":"Am J Pharm Educ"},{"key":"B27","author":"Miochol","year":""},{"key":"B28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.intimp.2015.04.039","article-title":"pH-dependent hydrolysis of acetylcholine: consequences for non-neuronal acetylcholine","volume":"29","author":"Wessler","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"13821","DOI":"10.1021\/ja204116a","article-title":"The \u201cneutral\u201d hydrolysis of simple carboxylic esters in water and the rate enhancements produced by acetylcholinesterase and other carboxylic acid esterases","volume":"133","author":"Wolfenden","year":"2011","journal-title":"J Am Chem Soc"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1802503\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:53:10Z","timestamp":1780462390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1802503\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":29,"alternative-id":["10.3389\/fcvm.2026.1802503"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1802503","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"article-number":"1802503"}}